SCHEMBL4470608

SCHEMBL4470608

CCN(CC)C(=O)c1ccc(Cl)cc1C(F)(F)F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.49
MCOLN3 Q8TDD5 1/20 0.49
ALDH1A1 P00352 4/20 0.47
NPSR1 Q6W5P4 3/20 0.47
KDM4E B2RXH2 3/20 0.47
POLB P06746 2/20 0.47
MAPT P10636 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
CYP3A4 P08684 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.44
RAB9A P51151 2/20 0.44
POLQ O75417 1/20 0.44
TP53 P04637 1/20 0.44
MLYCD O95822 1/20 0.43
HSP90AA1 P07900 2/20 0.42
HSP90AB1 P08238 2/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
ALPL P05186 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29175212 0.83 KMT2A (0.49) KDM4EPOLBCYP3A4RAB9AMLYCD
SCHEMBL4465339 0.82 MLYCD (0.43) GAAMCOLN3NPSR1MLYCDHSP90AA1
SCHEMBL25568110 0.80 RAB9A (0.45) GAAMCOLN3ALDH1A1NPSR1KDM4E
SCHEMBL26020575 0.80 RAB9A (0.47) GAAMCOLN3ALDH1A1NPSR1KDM4E
SCHEMBL7306129 0.79 EPHX2 (0.46) GAAMCOLN3ALDH1A1NPSR1KDM4E
SCHEMBL4469871 0.78 TSHR (0.50) GAAALDH1A1MAPTSMN1; SMN2TP53
SCHEMBL31591114 0.77 RAB9A (0.50) GAAKDM4EMAPTSMN1; SMN2RAB9A
SCHEMBL7779187 0.77 RAB9A (0.50) GAAKDM4EMAPTSMN1; SMN2RAB9A
SCHEMBL427243 0.77 SMN1; SMN2 (0.59) ALDH1A1KDM4EMAPTSMN1; SMN2RAB9A
SCHEMBL28462798 0.77 RAB9A (0.50) KDM4EMAPTSMN1; SMN2RAB9APOLQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572805-B2 Pyrrolo(oxo)isoquinolines as 5HT ligands BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-11 US disclosed
EP-1778225-A2 PYRROLO(OXO)ISOQUINOLINES AS 5HT LIGANDS Bristol-Myers Squibb Company (US) 2007-05-02 EP disclosed
WO-2006019886-A2 PYRROLO(OXO)ISOQUINOLINES AS 5HT LIGANDS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-02-23 WO disclosed
US-20060014777-A1 Pyrrolo(oxo)isoquinolines as 5HT ligands BRISTOL-MYERS SQUIBB COMPANY 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014777-A1 Pyrrolo(oxo)isoquinolines as 5HT ligands HTR2B, OPRD1, HTR1B GAA 2711/4885MCOLN3 1377/4885ALDH1A1 2732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.